Physician profile
Mohammad Azam
NPI 1184688541
$57,629.36
in general payments reported to CMS, 2019-2025
41 companies · $9,796 in 2025
The $9,796 reported for 2025 was more than what 92% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,367 · 2020: $4,775 · 2021: $9,362 · 2022: $11K · 2023: $8,663 · 2024: $12K · 2025: $9,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $9,631 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,400.00 |
| Food and Beverage | $9,630.65 |
| Education | $212.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $42,256.66 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $2,975.46 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mallinckrodt Hospital Products INC. | $2,587.33 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,883.89 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $969.13 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $722.36 | 2020-2025 | Glassia |
| Genzyme Corporation | $683.00 | 2021-2025 | |
| Insmed, INC. | $633.99 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $628.11 | 2019-2025 | Prolastin-C Liquid |
| Amgen INC. | $626.49 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $534.63 | 2019-2024 | Yupelri |
| Electromed, INC. | $318.35 | 2019-2025 | Smartvest |
| Pfizer INC. | $313.29 | 2021-2025 | |
| Gilead Sciences, INC. | $259.08 | 2021-2023 | |
| Philips North America LLC | $210.78 | 2019-2025 | Vest Therapy Und |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $199.50 | 2019 | |
| Genentech USA, INC. | $187.58 | 2019-2023 | Xolair |
| Baxter Healthcare | $174.15 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Sunovion Pharmaceuticals INC. | $148.70 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $147.74 | 2019-2020 | |
| Csl Behring | $132.14 | 2019-2025 | Hizentra, Kcentra |
| Ani Pharmaceuticals, INC. | $128.84 | 2023-2024 | Purified Cortrophin Gel |
| Inogen, INC. | $110.72 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Astellas Pharma US INC | $105.97 | 2022-2024 | Cresemba |
| United Therapeutics Corporation | $97.00 | 2023-2024 | Tyvaso |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Portola Pharmaceuticals, LLC | $59.67 | 2019 | |
| La Jolla Pharmaceutical Company | $59.57 | 2021-2023 | Giapreza |
| Harmony Biosciences LLC | $55.51 | 2025 | |
| Novartis Pharmaceuticals Corporation | $53.55 | 2019 | |
| Verona Pharma, INC. | $46.81 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $42.34 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $34.34 | 2019-2023 | Opsumit |
| 3b Medical, INC. | $29.81 | 2025 | Luna |
| Viatris Specialty LLC | $28.25 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $23.10 | 2019 | |
| Sandoz INC. | $19.78 | 2024 | Treprostinil |
| Mayne Pharma Commercial LLC | $18.69 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.84 | 2022 | |
| Allergan, INC. | $14.62 | 2019 | |
| Shire North American Group INC | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Azam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.